|  |
| --- |
| The purpose of this worksheet is to provide support for investigators conducting an emergency use of unapproved drug, biologic, or device in a life threatening situation, or a compassionate **use** of an unapproved device that does not have an IDE, and to provide support **to** Designated Reviewers reviewing such uses. This worksheet is to be used when overseeing such uses. It does not need to be completed or retained. |
| Emergency Use of an Unapproved Drug or Biologic[[1]](#footnote-1) |
| 1. Exemption Criteria for Emergency Use of an Unapproved Drug or Biologic (Check if “Yes”. All must be checked)
 |
| [ ]  | The patient is (was) confronted by a disease or condition that is (was) either:[ ]  Life-threatening (diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival).[ ]  Severely debilitating (diseases or conditions that cause major irreversible morbidity). |
| [ ]  | The situation necessitates (necessitated) the use of the investigational drug or biologic. |
| [ ]  | No generally acceptable alternative for treating the patient is (was) available. |
| [ ]  | There is (was) insufficient time to obtain IRB approval. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician will report (has reported) the use to the IRB within 5 days with documentation that the above findings were met. |
| [ ]  | The FDA has (had) issued an IND. |
| [ ]  | The use is (was) **NOT** subject to DHHS regulation See WORKSHEET: Human Research Determination (HRP-310).[[2]](#footnote-2) |
| **Section 2 or 3 must be met** |
| 1. Consent Criteria (Check if “Yes”. All must be checked)
 |
| [ ]  | Informed consent will be (was) sought from the patient or the patient’s legally authorized representative, in accordance with and to the extent required by 21 CFR §50. See WORKSHEET: Criteria for Approval and Other Considerations (HRP-314). |
| [ ]  | Informed consent will be (was) documented using TEMPLATE CONSENT DOCUMENT: Emergency Use (HRP-506) in accordance with and to the extent required by 21 CFR §50.27. See WORKSHEET: Criteria for Approval and Other Considerations (HRP-314). |
| 1. Exception Criteria for Consent (Check if “Yes”. All must be checked)
 |
| [ ]  | The patient is (was) confronted by a life-threatening situation necessitating the use of the test article. |
| [ ]  | Informed consent cannot (could not) be obtained from the patient because of an inability to communicate with, or obtain legally effective consent from, the patient. |
| [ ]  | Time is (was) insufficient to obtain consent from the patient’s legally authorized representative. |
| [ ]  | There is (was) no available alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the patient. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician will report (has reported) the use to the IRB within 5 days with documentation that the above findings were met. |
| [ ]  | A physician uninvolved in the clinical investigation will certify (has certified) in the medical record that the above findings were met. |
| [ ]  | A physician uninvolved in the clinical investigation will certify (has certified) to the IRB within 5 days that the above findings were met. |
| [ ]  | If certification took place after the use of the drug or biologic, all of the following are true: **(“N/A” if certification took place before the use)** |
|  | [ ]  | Immediate use of the test article is (was), in the investigator's opinion, required to preserve the life of the patient |
| [ ]  | There is (was) insufficient time to obtain the independent determination of a physician uninvolved in the clinical investigation. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician’s report to the IRB within 5 days will document that the above findings were met. |
| Emergency Use of an Unapproved Device[[3]](#footnote-3) |
| 1. Criteria for Emergency Use of an Unapproved Device (Check if “Yes” or “N/A”. All must be checked)
 |
| [ ]  | The patient is (was) confronted by a life-threatening disease or a serious condition requiring immediate use of the device. |
| [ ]  | The situation necessitates (necessitated) the immediate use of the device. |
| [ ]  | No generally acceptable alternative for treating the patient is (was) available. |
| [ ]  | There is (was) insufficient time to use existing procedures to obtain FDA approval of an IDE. |
| [ ]  | There is (was) substantial reason to believe that benefits will (would) exist. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician will report (has reported) the use to the IRB within 5 days with documentation that the above findings were met. |
| [ ]  | A physician uninvolved in the emergency use will certify (has certified) in the medical record that the above findings were met. |
| [ ]  | A physician uninvolved in the emergency use will certify (has certified) to the IRB within 5 days that the above findings were met.[[4]](#footnote-4) |
| [ ]  | One of the following is true:[ ]  There is (was) no IDE.[ ]  The treating physician wants (wanted) to use the device in a way not approved under an existing IDE.[ ]  The treating physician is (was) not part of the IDE study. |
| [ ]  | One of the following is true:[ ]  There is an IDE and the treating physician has (had) authorization from the sponsor.[ ]  There is no IDE and the treating physician will notify (has notified) FDA of the emergency use within 5 days |
| [ ]  | The use is (was) **NOT** subject to DHHS regulation See WORKSHEET: Human Research Determination (HRP-310). |
| **Section 5 or 6 must be met** |
| 1. Consent Criteria (Check if “Yes”. All must be checked)
 |
| [ ]  | Informed consent will be (was) sought from the patient or the patient’s legally authorized representative.[[5]](#footnote-5) |
| [ ]  | Informed consent will be (was) documented using TEMPLATE CONSENT DOCUMENT: Emergency Use (HRP-506).[[6]](#footnote-6) |
| 1. Exception Criteria for Consent (Check if “Yes”. All must be checked)
 |
| [ ]  | The patient is (was) confronted by a life-threatening situation necessitating the use of the test article. |
| [ ]  | Informed consent cannot (could not) be obtained from the patient because of an inability to communicate with, or obtain legally effective consent from, the patient. |
| [ ]  | Time is (was) insufficient to obtain consent from the patient’s legal representative. |
| [ ]  | There is (was) no available alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the patient. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician will report (has reported) the use to the IRB within 5 days with documentation that the above findings were met. |
| [ ]  | A physician uninvolved in the clinical investigation will certify (has certified) in the medical record that the above findings were met. |
| [ ]  | A physician uninvolved in the clinical investigation will certify (has certified) to the IRB within 5 days that the above findings were met. |
| [ ]  | If certification took place after the use of the drug or biologic, all of the following are true: **(“N/A” if certification took place before the use)** |
|  | [ ]  | Immediate use of the test article is (was), in the investigator's opinion, required to preserve the life of the patient |
| [ ]  | There is (was) insufficient time to obtain the independent determination of a physician uninvolved in the clinical investigation. |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician’s report to the IRB within 5 days will document that the above findings were met. |
| Compassionate Use of an Unapproved Device Being Used Without an IDE[[7]](#footnote-7) |
| 1. Criteria for Compassionate Use of an Unapproved Device (Check if “Yes” or “N/A”. All must be checked)
 |
| [ ]  | The patient is (was) confronted by a serious disease or condition. |
| [ ]  | No generally acceptable alternative for treating, diagnosing, or monitoring the patient is (was) available. |
| [ ]  | The probable risk to the patient is (was) not greater than the probable risk from the disease |
| [ ]  | The treating physician will document (has documented) in the medical record that the above findings were met. |
| [ ]  | The treating physician will report (has reported) the use to the IRB within 5 days with documentation that the above findings were met. |
| [ ]  | A physician uninvolved in the compassionate use will certify (has certified) in the medical record that the above findings were met. |
| [ ]  | A physician uninvolved in the compassionate use will certify (has certified) to the IRB within 5 days that the above findings were met. |
| [ ]  | The treating physician has concurrence from FDA for the use. |
| [ ]  | All institutional clearances have been obtained. |
| [ ]  | The treating physician will report any problems as a result of the device use to the IRB and sponsor. |
| [ ]  | The treating physician will write a summary of the use and give it to the sponsor or the FDA. |
| [ ]  | The use is (was) **NOT** subject to DHHS regulation See WORKSHEET: Human Research Determination (HRP-310). |
| 1. Consent criteria (Check if “Yes”. All must be checked)
 |
| [ ]  | Informed consent will be (was) sought from the patient or the patient’s legally authorized representative.[[8]](#footnote-8) |
| [ ]  | Informed consent will be (was) documented using TEMPLATE CONSENT DOCUMENT: Emergency Use (HRP-506).[[9]](#footnote-9) |

1. Emergency use of an unapproved drug or biologic is a clinical investigation and must comply with 21 CFR §50 and 21 CFR §56. [↑](#footnote-ref-1)
2. If the treating physician believes s/he may need to use this test article in a similar emergency situation, s/he must submit a protocol for the use within 25 business days. [↑](#footnote-ref-2)
3. Under FDA regulations, the emergency use of a test article, other than a medical device, is a clinical investigation, the patient is a participant, and the FDA may require data from an emergency use to be reported in a marketing application.

FDA does not consider the emergency use of an unapproved device to be clinical investigation and FDA does not require compliance with 21 CFR §50 and 21 CFR §56. The requirements are based on FDA guidance at <http://www.fda.gov/downloads/Training/CDRHLearn/UCM180888.pdf>, <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm#compassionateuse>, and <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127067.pdf>. [↑](#footnote-ref-3)
4. This may take place before or after the use. [↑](#footnote-ref-4)
5. FDA does not require the consent process to follow the informed consent requirements at 21 CFR §50. [↑](#footnote-ref-5)
6. FDA does not require the documentation of consent to follow the informed consent requirements at 21 CFR §50.27. [↑](#footnote-ref-6)
7. FDA does not consider the compassionate use of an unapproved device being used without an IDE to be a clinical investigation and FDA does not require compliance with 21 CFR §50 and 21 CFR §56. The requirements are based on FDA guidance at <http://www.fda.gov/downloads/Training/CDRHLearn/UCM180888.pdf>, <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm#compassionateuse>, and <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127067.pdf>. [↑](#footnote-ref-7)
8. FDA does not require the consent process to follow the informed consent requirements at 21 CFR §50. [↑](#footnote-ref-8)
9. FDA does not require the documentation of consent to follow the informed consent requirements at 21 CFR §50.27. [↑](#footnote-ref-9)